IN2014MN02114A - - Google Patents

Info

Publication number
IN2014MN02114A
IN2014MN02114A IN2114MUN2014A IN2014MN02114A IN 2014MN02114 A IN2014MN02114 A IN 2014MN02114A IN 2114MUN2014 A IN2114MUN2014 A IN 2114MUN2014A IN 2014MN02114 A IN2014MN02114 A IN 2014MN02114A
Authority
IN
India
Prior art keywords
akt3
emt
epithelial
occurrence
subject
Prior art date
Application number
Other languages
English (en)
Inventor
Jim Lorens
Crina Tiron
Original Assignee
Bergenbio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bergenbio As filed Critical Bergenbio As
Publication of IN2014MN02114A publication Critical patent/IN2014MN02114A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
IN2114MUN2014 2012-05-02 2013-05-02 IN2014MN02114A (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641512P 2012-05-02 2012-05-02
GB201207722A GB201207722D0 (en) 2012-05-02 2012-05-02 Method
PCT/IB2013/053488 WO2013164788A2 (en) 2012-05-02 2013-05-02 Method

Publications (1)

Publication Number Publication Date
IN2014MN02114A true IN2014MN02114A (cs) 2015-09-04

Family

ID=46330714

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2114MUN2014 IN2014MN02114A (cs) 2012-05-02 2013-05-02

Country Status (13)

Country Link
US (2) US10317405B2 (cs)
EP (1) EP2845004A2 (cs)
JP (2) JP2015525060A (cs)
KR (1) KR102179389B1 (cs)
CN (1) CN104335046B (cs)
AU (1) AU2013255456B2 (cs)
BR (1) BR112014027219A2 (cs)
CA (1) CA2871352A1 (cs)
EA (1) EA201401201A1 (cs)
GB (1) GB201207722D0 (cs)
IN (1) IN2014MN02114A (cs)
SG (1) SG11201407032WA (cs)
WO (1) WO2013164788A2 (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
GB201420239D0 (en) * 2014-11-14 2014-12-31 Bergenbio As Biomarker
GB201512133D0 (en) * 2015-07-10 2015-08-19 Bergenbio As Biomarkers
KR101941054B1 (ko) * 2016-07-20 2019-01-23 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102080384B1 (ko) * 2018-02-28 2020-02-21 주식회사 마크로젠 암줄기세포 특이적 바이오마커
JP7612576B2 (ja) * 2018-11-12 2025-01-14 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ がんの細胞状態移行を操作するための方法
CN115956078A (zh) * 2020-05-08 2023-04-11 乔治穆内有限责任公司 Akt3调节剂及其使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809194B1 (en) 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
US20040121413A1 (en) 2002-12-20 2004-06-24 Aebersold Rudolf H. Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2004086038A2 (en) * 2003-03-28 2004-10-07 Institut Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
US7414055B2 (en) * 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
WO2008042867A2 (en) * 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
CA2695330C (en) * 2007-07-12 2017-06-13 University Of South Florida Inhibitors of akt/pkb with anti-tumor activity
CA2696402A1 (en) * 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2009082488A2 (en) 2007-12-24 2009-07-02 Bergenbio As Methods for creating and identifying functional rna interference elements
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2010204578B2 (en) 2009-01-16 2016-05-12 Rigel Pharmaceuticals, Inc. AXL inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
EP2409156A4 (en) 2009-02-06 2013-07-17 H Lee Moffitt Cancer Ct & Res PHOSPHORYLATION OF ACT-TYROSINE 176 AS CANCER BIOMARKER
SG174356A1 (en) * 2009-03-13 2011-10-28 Bergen Teknologioverforing As Methods using axl as a biomarker of epithelial-to-mesnchymal transition
WO2010115119A2 (en) 2009-04-02 2010-10-07 Tufts Medical Center, Inc. Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents
WO2011050351A2 (en) 2009-10-23 2011-04-28 The Translational Genomics Research Institute Methods and kits used in identifying glioblastoma
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US20120028264A1 (en) 2010-07-27 2012-02-02 Steven Shak Method for using gene expression to determine prognosis of prostate cancer
WO2012032143A1 (en) * 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US20140031251A1 (en) * 2010-11-03 2014-01-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of classifying human subjects with regard to cancer prognosis

Also Published As

Publication number Publication date
JP2015525060A (ja) 2015-09-03
JP6738755B2 (ja) 2020-08-12
US20200072839A1 (en) 2020-03-05
KR20150016518A (ko) 2015-02-12
CN104335046A (zh) 2015-02-04
BR112014027219A2 (pt) 2017-06-27
CA2871352A1 (en) 2013-11-07
GB201207722D0 (en) 2012-06-13
CN104335046B (zh) 2019-10-11
KR102179389B1 (ko) 2020-11-18
EA201401201A1 (ru) 2015-02-27
EP2845004A2 (en) 2015-03-11
AU2013255456A1 (en) 2014-11-13
AU2013255456B2 (en) 2018-07-26
US20150119475A1 (en) 2015-04-30
JP2017136077A (ja) 2017-08-10
WO2013164788A3 (en) 2014-01-23
SG11201407032WA (en) 2014-11-27
US10317405B2 (en) 2019-06-11
WO2013164788A2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
IN2014MN02114A (cs)
IL245337A0 (en) Combinations of checkpoint inhibitors and cancer drugs
TWD159653S (zh) 個人電腦（一）
TWD165363S (zh) 錶殼
BR112013010099A2 (pt) boronatos como inibidores de arginase
TWD162033S (zh) 手錶
WO2010103388A8 (en) Methods using axl as a biomarker of epithelial-to-mesnchymal transition
UA118658C2 (uk) СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα
BR112015002286A2 (pt) aptâmeros epcam para a detecção de células tronco cancerosas
WO2013186639A8 (en) Methylation biomarkers for breast cancer
MX367255B (es) Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
PH12014502382A1 (en) Anti-robo4-antibody
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
SG10201506881PA (en) Biomarkers for cancers responsive to modulators of hec1 activity
MX345702B (es) Aparato y metodos de inversion de datos.
EA201492152A1 (ru) Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций
TWD172356S (zh) 錶殼
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
TWD158434S (zh) 個人電腦（二）
TWD158435S (zh) 個人電腦（三）
NZ631749A (en) Methods of treating cancer using angiogenin or an angiogenin agonist
MX2013005759A (es) Metodos para detectar bajo grado de inflamacion.
NZ703905A (en) Method of treating multiple sclerosis by using narrow band uvb
IN2014MN01871A (cs)
PH12016500541A1 (en) Use of odiparcil in the treatment of a mucopolysaccharidosis